Tenet Healthcare (NYSE:THC) Director Christopher Lynch Sells 3,837 Shares of Stock

Tenet Healthcare Corporation (NYSE:THC) Director Christopher Lynch sold 3,837 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $2,329,233.92. This trade represents a 28.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tenet Healthcare Trading Up 7.8%

Shares of Tenet Healthcare stock opened at $262.36 on Wednesday. The company has a 50 day simple moving average of $187.59 and a two-hundred day simple moving average of $198.22. The firm has a market cap of $22.60 billion, a PE ratio of 10.12, a PEG ratio of 1.37 and a beta of 1.27. Tenet Healthcare Corporation has a 1 year low of $155.02 and a 1 year high of $262.68. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings data on Friday, July 24th. The company reported $6.12 earnings per share for the quarter, beating the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The firm had revenue of $6.04 billion for the quarter, compared to analysts’ expectations of $5.43 billion. During the same quarter last year, the company posted $4.02 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. Analysts expect that Tenet Healthcare Corporation will post 20.9 earnings per share for the current fiscal year.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong Q2 results and improved outlook: Tenet beat analyst expectations for both earnings and revenue, while raising its 2026 forecast. Performance was driven by solid same-facility growth and disciplined expense management, reinforcing the company’s operating momentum. Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook
• Positive Sentiment: Analysts raise price targets: Truist increased its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” The upgrades suggest analysts see further upside following the earnings beat and improved guidance. Analyst price-target updates
• Positive Sentiment: Growth-stock appeal: Zacks highlighted Tenet as a highly ranked growth stock, which could attract additional interest from growth, value and momentum-focused investors. Tenet Healthcare Is a Top-Ranked Growth Stock
• Neutral Sentiment: Mixed analyst signal: Robert W. Baird lifted its target sharply to $280 from $210 but retained a “neutral” rating, indicating improved valuation expectations without a full shift to a bullish stance. Analyst price-target update
• Negative Sentiment: Executive and director stock sales: EVP Paola M. Arbour sold 10,878 shares worth approximately $2.65 million, reducing her position by 37.14%. Director Christopher S. Lynch sold 3,837 shares worth about $934,000, cutting his ownership by 28.62%. Although these sales may be for personal or tax-related reasons, the sizable transactions could create a modest overhang for THC. Tenet Healthcare insider transaction filing

Analyst Ratings Changes

Several analysts have issued reports on the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $305.00 target price on shares of Tenet Healthcare in a research note on Tuesday. Barclays upped their price objective on shares of Tenet Healthcare from $240.00 to $271.00 and gave the company an “overweight” rating in a research note on Friday. TD Cowen lifted their target price on shares of Tenet Healthcare from $233.00 to $263.00 and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company upped their price target on shares of Tenet Healthcare from $213.00 to $231.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Royal Bank Of Canada lifted their price objective on Tenet Healthcare from $236.00 to $283.00 and gave the stock an “outperform” rating in a report on Monday. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $268.50.

Institutional Investors Weigh In On Tenet Healthcare

Large investors have recently added to or reduced their stakes in the company. Triumph Capital Management bought a new position in shares of Tenet Healthcare during the third quarter valued at about $25,000. Activest Wealth Management purchased a new position in Tenet Healthcare during the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in Tenet Healthcare during the 4th quarter valued at approximately $29,000. Canada Pension Plan Investment Board bought a new stake in shares of Tenet Healthcare in the 2nd quarter worth approximately $35,000. Finally, Meeder Asset Management Inc. increased its stake in shares of Tenet Healthcare by 146.2% during the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after buying an additional 114 shares during the period. Institutional investors own 95.44% of the company’s stock.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.